Trial of Hypofractionated Intensity Modulated Radiation Therapy With Temozolomide and Granulocyte-macrophage Colony-stimulating Factor for Patients With Newly Diagnosed Glioblastoma Multiforme

NCT02663440 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

41

Enrollment

OTHER

Sponsor class

Conditions

Glioblastoma Multiforme

Interventions

RADIATION: Hypofractionated IMRT
BIOLOGICAL: Granulocyte-macrophage Colony-stimulating Factor
DRUG: Temozolomide

Sponsor

Zhejiang Cancer Hospital